SCHEMBL517090

SCHEMBL517090

CNS(=O)(=O)c1ccc2cc[nH]c2c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 5/20 0.56
CYP19A1 P11511 1/20 0.56
L3MBTL1 Q9Y468 1/20 0.54
TAS2R14 Q9NYV8 1/20 0.54
HTR6 P50406 2/20 0.52
HDAC3 O15379 1/20 0.50
HDAC4 P56524 1/20 0.50
HDAC1 Q13547 1/20 0.50
HDAC7 Q8WUI4 1/20 0.50
HDAC2 Q92769 1/20 0.50
HDAC10 Q969S8 1/20 0.50
HDAC11 Q96DB2 1/20 0.50
HDAC8 Q9BY41 1/20 0.50
HDAC6 Q9UBN7 1/20 0.50
HDAC9 Q9UKV0 1/20 0.50
HDAC5 Q9UQL6 1/20 0.50
LMNA P02545 1/20 0.50
PNMT P11086 1/20 0.45
GAA P10253 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31591390 1.00 ESR1 (0.56) ESR1CYP19A1L3MBTL1TAS2R14HTR6
SCHEMBL5254762 0.86 L3MBTL1 (0.54) ESR1CYP19A1L3MBTL1TAS2R14HTR6
SCHEMBL31122029 0.82 ESR1 (0.52) ESR1CYP19A1HTR6HDAC3HDAC4
SCHEMBL773249 0.82 ESR1 (0.52) ESR1CYP19A1HTR6HDAC3HDAC4
SCHEMBL30260844 0.80 ESR1 (0.53) ESR1CYP19A1HTR6HDAC3HDAC4
SCHEMBL1144770 0.80 ESR1 (0.53) ESR1CYP19A1HTR6HDAC3HDAC4
SCHEMBL16719331 0.80 ESR1 (0.78) ESR1CYP19A1HTR6HDAC3HDAC4
SCHEMBL5351271 0.80 ESR1 (0.50) ESR1CYP19A1HTR6HDAC3HDAC4
SCHEMBL17845303 0.80 PARG (0.54) ESR1CYP19A1HTR6
SCHEMBL21101921 0.79 ATIC (0.52) L3MBTL1TAS2R14HTR6LMNAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260124197-A1 NOVEL HETEROBICYCLIC COMPOUND FOR INHIBITING YAP-TEAD INTERACTION AND PHARMACEUTICAL COMPOSITION COMPRISING SAME HANMI PHARMACEUTICAL CO LTD (KR) 2026-05-07 US disclosed
EP-4581026-A1 NOVEL HETEROBICYCLIC COMPOUND FOR INHIBITING YAP-TEAD INTERACTION AND PHARMACEUTICAL COMPOSITION COMPRISING SAME Hanmi Pharm. Co., Ltd. (KR) 2025-07-09 EP disclosed
CN-120051465-A Novel heterobicyclic compounds for inhibiting YAP-TEAD interactions and pharmaceutical compositions containing the same 韩美药品株式会社 2025-05-27 CN disclosed
US-20240360165-A1 INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) MEDIC LIFE SCIENCES, INC. 2024-10-31 US disclosed
WO-2024080792-A1 NOVEL HETEROBICYCLIC COMPOUND FOR INHIBITING YAP-TEAD INTERACTION AND PHARMACEUTICAL COMPOSITION COMPRISING SAME HANMI PHARM. CO., LTD. (KR) 2024-04-18 WO disclosed
WO-2024080792-A1 NOVEL HETEROBICYCLIC COMPOUND FOR INHIBITING YAP-TEAD INTERACTION AND PHARMACEUTICAL COMPOSITION COMPRISING SAME HANMI PHARM. CO., LTD. (KR) 2024-04-18 WO disclosed
EP-4295852-A2 PIPERIDINE DERIVATIVES AS INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) Syros Pharmaceuticals, Inc. (US) 2023-12-27 EP disclosed
EP-3484871-B1 PIPERIDINE DERIVATIVES AS INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) SYROS PHARMACEUTICALS INC (US) 2023-06-07 EP disclosed
EP-3484871-B1 PIPERIDINE DERIVATIVES AS INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) SYROS PHARMACEUTICALS INC (US) 2023-06-07 EP disclosed
US-20230062491-A1 INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) MEDIC LIFE SCIENCES, INC. 2023-03-02 US disclosed
US-20120329784-A1 COMPOUNDS AND METHODS GLAXOSMITHKLINE LLC 2012-12-27 US disclosed
EP-2523559-A1 COMPOUNDS AND METHODS GlaxoSmithKline LLC (US) 2012-11-21 EP disclosed
CN-102791131-A Compounds and methods GLAXOSMITHKLINE LLC 2012-11-21 CN disclosed
US-20120028969-A1 BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS AND USES THEREOF NOVARTIS AG (CH) 2012-02-02 US disclosed
WO-2011088027-A1 COMPOUNDS AND METHODS GLAXOSMITHKLINE LLC (US) 2011-07-21 WO disclosed
WO-2011088027-A1 COMPOUNDS AND METHODS GLAXOSMITHKLINE LLC (US) 2011-07-21 WO disclosed
EP-0227823-B1 COLOR TRANSFER PHOTOGRAPHIC PROCESSES AND PRODUCTS POLAROID CORPORATION (US) 1989-03-22 EP disclosed
EP-0227823-A1 COLOR TRANSFER PHOTOGRAPHIC PROCESSES AND PRODUCTS. POLAROID CORP (US) 1987-07-08 EP disclosed
WO-1987000307-A1 COLOR TRANSFER PHOTOGRAPHIC PROCESSES AND PRODUCTS POLAROID CORPORATION (US) 1987-01-15 WO disclosed
US-4615966-A Color transfer photographic processes and products with indole phthalein filter dyes POLAROID CORPORATION (US) 1986-10-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260124197-A1 NOVEL HETEROBICYCLIC COMPOUND FOR INHIBITING YAP-TEAD INTERACTION AND PHARMACEUTICAL COMPOSITION COMPRISING SAME YAP1, RCC1, YES1 ESR1 3041/4885CYP19A1 3038/4885L3MBTL1 1800/4885
US-20120329784-A1 COMPOUNDS AND METHODS RB1, DHFR, NQO1 ESR1 76/4885CYP19A1 30/4885L3MBTL1 1654/4885
US-20120028969-A1 BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS AND USES THEREOF ACACA, ACACB, COASY ESR1 4706/4885CYP19A1 359/4885L3MBTL1 4449/4885
US-20240360165-A1 INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) CDK7, CDK3, CDK9 ESR1 2320/4885CYP19A1 832/4885L3MBTL1 2140/4885
US-20230062491-A1 INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) CDK7, CDK3, CDK9 ESR1 2320/4885CYP19A1 832/4885L3MBTL1 2140/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.